A phase 1b randomised, placebo-controlled trial of nabiximols cannabinoid oromucosal spray with...
Updated: Apr 28, 2021
... temozolomide in patients with recurrent glioblastoma.
BACKGROUND: Preclinical data suggest some cannabinoids may exert antitumour effects against glioblastoma (GBM). Safety and preliminary efficacy of nabiximols oromucosal cannabinoid spray plus dose-intense temozolomide (DIT) was evaluated in patients with first recurrence of GBM.
Source: British Journal of Cancer via nature.com